Brian Stuglik Sells Shares of PBYI
Brian Stuglik sold 8,100 shares of PBYI on June 12, 2026, for $58,320.
Key Points
- Brian Stuglik sold 8,100 shares of PBYI on June 12, 2026, at an average price of $7.20, totaling $58,320.
- PBYI shares currently trade at $7.33, with a notable insider transaction by Stuglik and others on the same date.
- Peer funds like BlackRock and Renaissance Technologies adjusted their PBYI positions, showing varied institutional interest.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 12, 2026, Brian Stuglik sold 8,100 shares of PBYI at an average price of $7.20 per share. This transaction was valued at $58,320 and was part of a planned sale under Rule 10b5-1. PBYI shares were trading at around $7.33 at the time.
Insider Buying and Selling at Puma Biotechnology, Inc.
Several insiders at PBYI engaged in stock transactions on June 12, 2026. Alongside Brian Stuglik, other insiders like Dorval Allison and Adrian Senderowicz also sold shares, each disposing of 11,610 and 27,000 shares respectively, at an average price of $7.20. Jay Moyes sold 22,000 shares at $7.22, while Troy Edward Wilson sold 10,800 shares at $7.20. These sales were planned transactions.
Other Institutional Activity in PBYI
Institutional investors have shown varied activity in PBYI. Acorn Capital Advisors maintained its position with 4,131,299 shares valued at about $26.4 million. BlackRock trimmed its holdings by 43,636 shares, ending with 3,598,952 shares worth approximately $23 million. Meanwhile, Acadian Asset Management increased its stake by 16,936 shares to hold 2,041,759 shares valued at $13 million. Renaissance Technologies reduced its position by 181,400 shares, now holding 1,942,413 shares valued at $12.4 million. American Century Companies added 266,209 shares, bringing its total to 1,916,346 shares worth about $12.2 million.
Analysts Set New Price Targets
Analysts have maintained their outlook on PBYI. On February 28, 2025, HC Wainwright & Co. reiterated a 'buy' rating with a price target of $7.00. TD Cowen maintained a 'hold' rating with a $4.00 target on May 20, 2024, while Barclays maintained a 'sell' rating with a $2.00 target on May 3, 2024. The consensus among analysts is cautious, with varied ratings reflecting differing expectations.
Bottom Line
Brian Stuglik's planned sale of PBYI shares highlights ongoing insider activity. While insider transactions can provide insight, they are not definitive signals of future performance. Investors often track these moves as part of a broader analysis. Institutional and analyst perspectives remain mixed, indicating diverse views on PBYI's potential. As always, it's important to remember that 13F filings and insider transactions are backward-looking and don't necessarily reflect the current market position.
Get Puma Biotechnology, Inc. alerts
New 13F filings, insider trades, and analyst moves on $PBYI, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.